NASDAQ:SRRA - Sierra Oncology Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.46 -0.02 (-1.35 %) (As of 05/19/2019 01:10 PM ET)Previous Close$1.46Today's Range$1.42 - $1.4752-Week Range$1.05 - $3.70Volume190,296 shsAverage Volume408,708 shsMarket Capitalization$109.05 millionP/E RatioN/ADividend YieldN/ABeta1.7 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sierra Oncology, Inc., a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control. The company is also advancing SRA737, which is being investigated in two Phase 1/2 clinical trials primarily focused on patients with ovarian cancer; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada. Receive SRRA News and Ratings via Email Sign-up to receive the latest news and ratings for SRRA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRRA Previous SymbolNASDAQ:DNAI CUSIPN/A CIK1290149 Webwww.sierraoncology.com Phone604-558-6536Debt Debt-to-Equity Ratio0.06 Current Ratio13.07 Quick Ratio13.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.12 per share Price / Book1.30Profitability EPS (Most Recent Fiscal Year)($0.75) Net Income$-53,330,000.00 Net MarginsN/A Return on Equity-54.06% Return on Assets-48.30%Miscellaneous Employees79 Outstanding Shares74,690,000Market Cap$109.05 million Next Earnings Date8/8/2019 (Estimated) OptionableOptionable Sierra Oncology (NASDAQ:SRRA) Frequently Asked Questions What is Sierra Oncology's stock symbol? Sierra Oncology trades on the NASDAQ under the ticker symbol "SRRA." How were Sierra Oncology's earnings last quarter? Sierra Oncology Inc (NASDAQ:SRRA) issued its quarterly earnings data on Wednesday, May, 8th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.04. View Sierra Oncology's Earnings History. When is Sierra Oncology's next earnings date? Sierra Oncology is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Sierra Oncology. What is the consensus analysts' recommendation for Sierra Oncology? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sierra Oncology in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sierra Oncology. Has Sierra Oncology been receiving favorable news coverage? Media coverage about SRRA stock has been trending positive on Sunday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Sierra Oncology earned a daily sentiment score of 2.2 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future. Who are some of Sierra Oncology's key competitors? Some companies that are related to Sierra Oncology include Albireo Pharma (ALBO), Vital Therapies (VTL), Achillion Pharmaceuticals (ACHN), DiaMedica Therapeutics (DMCAF), Arcus Biosciences (RCUS), Collegium Pharmaceutical (COLL), Savara (SVRA), Kalvista Pharmaceuticals (KALV), Dynavax Technologies (DVAX), Cyclerion Therapeutics (CYCN), BioDelivery Sciences International (BDSI), Progenics Pharmaceuticals (PGNX), Kezar Life Sciences (KZR), Catalyst Pharmaceuticals (CPRX) and Assembly Biosciences (ASMB). What other stocks do shareholders of Sierra Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sierra Oncology investors own include Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Ardelyx (ARDX), Viking Therapeutics (VKTX), AcelRx Pharmaceuticals (ACRX), Athersys (ATHX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL) and Global Blood Therapeutics (GBT). Who are Sierra Oncology's key executives? Sierra Oncology's management team includes the folowing people: Dr. Nicholas R. Glover, Pres, CEO & Director (Age 50)Dr. Barbara Klencke, Chief Devel. Officer (Age 62)Dr. Mark M. Kowalski, Chief Medical Officer (Age 64)Mr. Sukhi Jagpal CA, CPA, CBV, MBA, Chief Financial Officer (Age 45)Dr. Keith E. Anderson Ph.D., Sr. VP of Technical Operations (Age 50) Who are Sierra Oncology's major shareholders? Sierra Oncology's stock is owned by a number of of retail and institutional investors. Top institutional investors include Broadfin Capital LLC (6.47%), Prosight Management LP (3.29%), Renaissance Technologies LLC (2.54%), Dimensional Fund Advisors LP (1.32%), Morgan Stanley (1.14%) and Acadian Asset Management LLC (0.65%). View Institutional Ownership Trends for Sierra Oncology. Which major investors are selling Sierra Oncology stock? SRRA stock was sold by a variety of institutional investors in the last quarter, including Algert Global LLC, Prosight Management LP, Morgan Stanley, Broadfin Capital LLC, Oxford Asset Management LLP, Dimensional Fund Advisors LP, Spark Investment Management LLC and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for Sierra Oncology. Which major investors are buying Sierra Oncology stock? SRRA stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Acadian Asset Management LLC, Virtu Financial LLC, Brookstone Capital Management and Blair William & Co. IL. View Insider Buying and Selling for Sierra Oncology. How do I buy shares of Sierra Oncology? Shares of SRRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sierra Oncology's stock price today? One share of SRRA stock can currently be purchased for approximately $1.46. How big of a company is Sierra Oncology? Sierra Oncology has a market capitalization of $109.05 million. The biotechnology company earns $-53,330,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. Sierra Oncology employs 79 workers across the globe. What is Sierra Oncology's official website? The official website for Sierra Oncology is http://www.sierraoncology.com. How can I contact Sierra Oncology? Sierra Oncology's mailing address is 2150 - 885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. The biotechnology company can be reached via phone at 604-558-6536 or via email at [email protected] MarketBeat Community Rating for Sierra Oncology (NASDAQ SRRA)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 200 (Vote Outperform)Underperform Votes: 178 (Vote Underperform)Total Votes: 378MarketBeat's community ratings are surveys of what our community members think about Sierra Oncology and other stocks. Vote "Outperform" if you believe SRRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRRA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: Gap Up Stocks Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.